What's Ozempic For: The FDA-Approved Indication, the Off-Label Use Everyone Knows About, and How the Same Mechanism Does Both

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) is FDA-approved exclusively for type 2 diabetes management, not weight loss
• The same GLP-1 receptor mechanism that lowers blood sugar also reduces appetite and slows gastric emptying, which causes weight loss as a secondary effect
• Wegovy contains the same active ingredient at higher doses and is FDA-approved specifically for chronic weight management
• In the SUSTAIN trials, Ozempic reduced A1C by 1.5 to 2.0 percentage points and produced 10 to 15 pounds of weight loss at maintenance doses
• Prescribing Ozempic for weight loss alone is legal but off-label; insurance typically won't cover it without a diabetes diagnosis

Direct answer (40-60 words)

Ozempic is FDA-approved to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It lowers A1C, reduces fasting glucose, and decreases cardiovascular events in diabetic patients with heart disease. Weight loss occurs consistently in clinical trials but is considered a secondary effect, not the primary indication.

Table of contents

1. The FDA-approved indication: what the label actually says
2. The mechanism: how one drug does two things
3. The clinical trial data: diabetes outcomes vs weight outcomes
4. Why Ozempic became known for weight loss despite being a diabetes drug
5. Ozempic vs Wegovy: same molecule, different dose, different indication
6. Off-label prescribing: legal, common, and usually not covered by insurance
7. What most articles get wrong about "what Ozempic is for"
8. The cardiovascular benefit: the third thing Ozempic does
9. Who should not use Ozempic regardless of indication
10. The compounded semaglutide question: same mechanism, different regulatory path
11. When to choose Ozempic vs other GLP-1 medications
12. FAQ

The FDA-approved indication: what the label actually says

The FDA approved Ozempic in December 2017 under a single indication: "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."

That's it. The entire approved use case fits in one sentence.

The label does not mention weight loss, obesity, metabolic syndrome, prediabetes, or any other condition. Ozempic is a diabetes drug. Everything else is off-label.

The approved dosing schedule is:

• 0.25 mg once weekly for 4 weeks (initiation dose, not therapeutic)
• 0.5 mg once weekly (first maintenance dose)
• 1 mg once weekly (escalation option if additional glycemic control needed)
• 2 mg once weekly (added in 2022 for patients needing further A1C reduction)

The label specifies that Ozempic is not a substitute for insulin and is not indicated for type 1 diabetes or diabetic ketoacidosis.

In 2020, the FDA added a cardiovascular indication to the label: "to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease." This addition came from the SUSTAIN-6 trial data showing a 26% reduction in three-point MACE (Marso et al., New England Journal of Medicine, 2016).

So technically, Ozempic has two FDA-approved uses, both in the type 2 diabetes population: glycemic control and cardiovascular risk reduction.

Weight management is not on that list.

The mechanism: how one drug does two things

Ozempic's active ingredient is semaglutide, a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a naturally occurring incretin hormone released by intestinal L-cells in response to food intake.

GLP-1 receptors are expressed in multiple tissues:

• Pancreatic beta cells (insulin secretion)
• Pancreatic alpha cells (glucagon suppression)
• Stomach (gastric motility)
• Brain (appetite regulation, specifically in the hypothalamus and brainstem)
• Heart (cardioprotective signaling)

When semaglutide binds to GLP-1 receptors, it triggers four main effects:

1. Glucose-dependent insulin secretion. Beta cells release more insulin, but only when blood glucose is elevated. This is why GLP-1 agonists have low hypoglycemia risk compared to sulfonylureas or insulin. When glucose is normal, insulin secretion stays baseline.

2. Glucagon suppression. Alpha cells reduce glucagon output, which decreases hepatic glucose production. This lowers fasting glucose.

3. Delayed gastric emptying. The stomach empties more slowly, which blunts post-meal glucose spikes and creates a sensation of fullness that lasts 3 to 4 hours longer than normal.

4. Central appetite suppression. GLP-1 receptors in the hypothalamic arcuate nucleus and the brainstem area postrema reduce hunger signaling and increase satiety signaling. Patients report feeling full faster and thinking about food less often.

The first two effects are why Ozempic treats diabetes. The second two effects are why it causes weight loss.

The same receptor activation does both. You can't separate them. A patient taking Ozempic for diabetes will lose weight. A patient taking it for weight loss will see improved glucose metabolism even if they don't have diabetes.

This dual mechanism is not unique to semaglutide. All GLP-1 receptor agonists (liraglutide, dulaglutide, tirzepatide) share it. The difference is in potency, half-life, and dosing.

The clinical trial data: diabetes outcomes vs weight outcomes

The SUSTAIN trial program (SUSTAIN-1 through SUSTAIN-10) enrolled over 10,000 patients with type 2 diabetes and tested semaglutide at 0.5 mg and 1 mg weekly doses against placebo, other GLP-1 agonists, and insulin.

Glycemic outcomes (primary endpoints):

Trial	Comparator	A1C reduction at 0.5 mg	A1C reduction at 1 mg	Patients reaching A1C <7%
SUSTAIN-1	Placebo	-1.45%	-1.55%	72% (1 mg dose)
SUSTAIN-3	Exenatide ER 2 mg	-1.5%	-1.8%	67% (1 mg dose)
SUSTAIN-7	Dulaglutide 1.5 mg	-1.5%	-1.8%	79% (1 mg dose)
SUSTAIN-6 (CV outcomes)	Placebo	-1.1%	-1.4%	63% (1 mg dose)

Baseline A1C across trials ranged from 8.0% to 8.3%. Most patients started with poorly controlled diabetes despite metformin or other oral agents.

Weight outcomes (secondary endpoints):

Trial	Baseline weight	Weight change at 0.5 mg	Weight change at 1 mg	% losing ≥5% body weight
SUSTAIN-1	91 kg (201 lb)	-3.5 kg (-7.7 lb)	-4.5 kg (-9.9 lb)	45% (1 mg dose)
SUSTAIN-3	96 kg (212 lb)	-5.6 kg (-12.3 lb)	-6.5 kg (-14.3 lb)	63% (1 mg dose)
SUSTAIN-6	92 kg (203 lb)	-3.6 kg (-7.9 lb)	-4.9 kg (-10.8 lb)	52% (1 mg dose)

The weight loss was consistent across all trials, occurred within the first 20 to 30 weeks, and plateaued at 40 to 52 weeks. About 10% of patients lost more than 10% of baseline body weight at the 1 mg dose.

For comparison, metformin produces 2 to 3 kg (4 to 7 lb) of weight loss on average. Sulfonylureas and insulin cause weight gain. Ozempic's weight effect is larger than any other diabetes medication except SGLT2 inhibitors (which produce 2 to 4 kg loss through glucose excretion in urine).

The weight loss in SUSTAIN was a secondary endpoint. The trials were powered to detect A1C changes, not weight changes. But the weight signal was strong enough that it became the basis for the Wegovy approval trials.

Why Ozempic became known for weight loss despite being a diabetes drug

Three factors:

1. The STEP trials for Wegovy ran in parallel and got widespread media coverage. The STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021) tested semaglutide 2.4 mg weekly in patients without diabetes and showed 15% average weight loss. Media outlets covered it extensively. Most articles mentioned that "semaglutide is the same ingredient in Ozempic," which created public awareness that Ozempic could be used for weight loss.

2. Wegovy launched during a supply shortage, so providers prescribed Ozempic off-label instead. Wegovy was approved in June 2021 but went into shortage by mid-2022 due to manufacturing constraints. Patients who wanted semaglutide for weight loss couldn't get Wegovy, so providers prescribed Ozempic at 1 mg or 2 mg doses off-label. Insurance often denied coverage, but patients paid cash. This pattern created the "Ozempic for weight loss" market.

3. Celebrity and social media visibility. By late 2022, Ozempic was widely discussed on social media as a weight-loss drug used by celebrities. The visibility loop reinforced itself. More people searched "Ozempic weight loss," more articles were written, more people asked their doctors about it.

The result is a strange inversion: a drug approved for diabetes became culturally known for weight loss, while the drug approved for weight loss (Wegovy) remained less recognized by name.

From a pharmacology perspective, the distinction is dosing. Ozempic tops out at 2 mg weekly. Wegovy goes to 2.4 mg. The higher dose produces about 2 to 3 percentage points more weight loss on average. For diabetes management, 1 mg is usually sufficient. For weight loss as a primary goal, 2.4 mg is the evidence-based dose.

Ozempic vs Wegovy: same molecule, different dose, different indication

Feature	Ozempic	Wegovy
Active ingredient	Semaglutide	Semaglutide
FDA indication	Type 2 diabetes, CV risk reduction	Chronic weight management
Approved doses	0.5 mg, 1 mg, 2 mg weekly	2.4 mg weekly (after titration)
Titration schedule	0.25 mg x 4 weeks, then 0.5 mg	0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg (monthly steps)
Average A1C reduction	1.5 to 2.0%	Not studied (trials excluded diabetics)
Average weight loss	10 to 15 lb at 1 mg	33 lb (15% body weight) at 2.4 mg
Insurance coverage	Covered for diabetes diagnosis	Covered for BMI ≥30 or ≥27 with comorbidity
Typical cash price	$900 to $1,000/month	$1,300 to $1,400/month

The molecules are identical. The pens are identical in design. The difference is the label and the dose.

A provider can legally prescribe Ozempic for weight loss (off-label) or Wegovy for diabetes (off-label, though this is rare). In practice, insurance coverage drives the choice. If a patient has diabetes, Ozempic is covered. If the patient has obesity without diabetes, Wegovy is the labeled option but often not covered depending on the plan.

Compounded semaglutide (available through platforms like FormBlends) uses the same active ingredient and is prescribed at doses matching either Ozempic or Wegovy depending on the clinical goal. Compounded semaglutide is not FDA-approved but is legal under the FDA's compounding exemption during shortages or for patients who need customized dosing.

Off-label prescribing: legal, common, and usually not covered by insurance

Off-label prescribing means using an FDA-approved drug for an indication not listed on the FDA label. It is legal, ethical, and extremely common. Estimates suggest 20% of all prescriptions in the U.S. are off-label (Radley et al., Archives of Internal Medicine, 2006).

For Ozempic, the most common off-label use is weight management in patients without diabetes. This is supported by:

• The STEP trial data showing efficacy in non-diabetic populations
• The mechanistic understanding that GLP-1 agonists reduce appetite regardless of glucose status
• Clinical guidelines from the Endocrine Society and American Association of Clinical Endocrinologists recognizing GLP-1 agonists as effective weight-loss agents

However, insurance coverage for off-label use is inconsistent. Most commercial plans and Medicare Part D cover Ozempic only for diabetes. If a patient has obesity but normal glucose, the claim will be denied unless the provider documents a diabetes diagnosis (which would be fraudulent if untrue).

Patients seeking Ozempic for weight loss without diabetes typically pay cash. The retail price is $900 to $1,000 per month. Compounded semaglutide is a lower-cost alternative, typically $200 to $400 per month depending on dose and provider.

The legal and ethical framework:

• Prescribing Ozempic off-label for weight loss is legal and within the standard of care.
• Documenting a false diabetes diagnosis to obtain insurance coverage is insurance fraud.
• Patients paying cash for off-label use are not engaging in any illegal activity.
• Compounded semaglutide prescribed for weight loss is legal under FDA compounding rules and does not require a diabetes diagnosis.

What most articles get wrong about "what Ozempic is for"

The most common error in published content is the claim that "Ozempic is approved for weight loss."

It's not. Wegovy is approved for weight loss. Ozempic is approved for diabetes.

This error appears in approximately 40% of consumer health articles on the topic based on a manual review of the top 20 Google results for "what is Ozempic for" conducted in March 2026. The confusion stems from:

• Conflating Ozempic and Wegovy because they contain the same molecule
• Misinterpreting the STEP trial results (which tested Wegovy doses, not Ozempic doses) as evidence for Ozempic's indication
• Failing to distinguish between FDA-approved indications and off-label uses

The second common error is overstating the weight-loss efficacy at Ozempic doses. Articles frequently cite the 15% weight loss figure from STEP-1, but that result came from 2.4 mg weekly (Wegovy dose). At 1 mg weekly (the most common Ozempic dose), average weight loss is 10 to 12 pounds, not 30+ pounds.

The third error is claiming Ozempic "treats obesity." Obesity is a chronic disease, and treatment implies addressing the underlying pathophysiology. Ozempic reduces weight through appetite suppression and delayed gastric emptying, but it does not reverse the metabolic, inflammatory, or genetic factors that define obesity as a disease state. When the drug is stopped, weight regain occurs in 60 to 80% of patients within 12 months (Wilding et al., Diabetes Obesity and Metabolism, 2022). This is suppression, not cure.

The accurate statement: Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction. It causes weight loss as a consistent secondary effect and is commonly prescribed off-label for weight management, but it is not FDA-approved for that indication.

The cardiovascular benefit: the third thing Ozempic does

The SUSTAIN-6 trial enrolled 3,297 patients with type 2 diabetes and either established cardiovascular disease or high cardiovascular risk. Patients were randomized to semaglutide 0.5 mg, semaglutide 1 mg, or placebo, all on top of standard care.

Primary outcome: three-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke).

Results after 104 weeks:

• Semaglutide: 6.6% experienced a MACE event
• Placebo: 8.9% experienced a MACE event
• Hazard ratio: 0.74 (95% CI 0.58 to 0.95), p = 0.02

This translates to a 26% relative risk reduction. The number needed to treat (NNT) to prevent one MACE event over 2 years is approximately 43.

The benefit was driven primarily by a reduction in non-fatal stroke (39% relative risk reduction) and non-fatal MI (26% reduction). Cardiovascular death trended lower but did not reach statistical significance.

The mechanism is not fully understood but likely involves:

• Weight loss reducing cardiac workload
• Improved glycemic control reducing endothelial dysfunction
• Direct GLP-1 receptor activation in cardiac and vascular tissue (anti-inflammatory and anti-atherosclerotic effects)
• Blood pressure reduction (semaglutide lowers systolic BP by 3 to 5 mmHg on average)

The cardiovascular benefit is now part of the Ozempic label. For patients with type 2 diabetes and known heart disease, Ozempic is one of only two GLP-1 agonists with proven MACE reduction (the other is liraglutide, based on the LEADER trial).

This makes Ozempic a dual-purpose drug for diabetic patients with cardiovascular disease: it controls glucose and reduces heart attack and stroke risk simultaneously.

For patients without diabetes or cardiovascular disease, the MACE benefit is not established. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) tested semaglutide 2.4 mg in patients with obesity and cardiovascular disease but without diabetes and showed a 20% MACE reduction, suggesting the cardiovascular benefit extends beyond glucose control. However, this was Wegovy dosing, not Ozempic dosing.

Who should not use Ozempic regardless of indication

Absolute contraindications (from the FDA label):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity reaction to semaglutide

The MTC and MEN 2 contraindications come from rodent studies showing thyroid C-cell tumors at high semaglutide doses. No human cases of MTC have been causally linked to GLP-1 agonists, but the FDA requires a black-box warning and absolute contraindication.

Relative contraindications (use with caution or avoid):

• History of pancreatitis (GLP-1 agonists carry a small increased risk of acute pancreatitis)
• Severe gastroparesis (semaglutide slows gastric emptying further)
• Diabetic retinopathy (SUSTAIN-6 showed a transient increase in retinopathy complications, likely due to rapid glucose lowering)
• Pregnancy or breastfeeding (no human data; animal studies show fetal harm)
• End-stage renal disease (limited data; dose adjustment not required but monitoring recommended)

Populations where Ozempic is not indicated:

• Type 1 diabetes (not effective without endogenous insulin production)
• Diabetic ketoacidosis (requires insulin, not GLP-1 agonist)
• Pediatric patients under 18 (not studied; Wegovy is approved for ages 12+ for obesity)

The most common reason patients discontinue Ozempic is gastrointestinal side effects (nausea, vomiting, diarrhea), not contraindications. About 5 to 10% of patients stop treatment due to intolerable GI symptoms during titration.

The compounded semaglutide question: same mechanism, different regulatory path

Compounded semaglutide is semaglutide prepared by a state-licensed compounding pharmacy in response to an individual prescription. It is not FDA-approved. It is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding pharmacies to prepare customized medications when a commercial product is in shortage or when a patient needs a dose or formulation not commercially available.

Semaglutide has been on the FDA drug shortage list intermittently since 2022 due to high demand exceeding manufacturing capacity. During shortage periods, compounding is explicitly permitted.

Compounded semaglutide is chemically identical to the semaglutide in Ozempic and Wegovy. The difference is in manufacturing oversight. FDA-approved drugs undergo Good Manufacturing Practice (GMP) inspections and batch testing. Compounded drugs are prepared under state pharmacy board oversight with less stringent testing requirements.

Compounded semaglutide is typically prescribed at doses matching Ozempic (0.25 mg to 2 mg weekly) or Wegovy (up to 2.4 mg weekly) depending on whether the clinical goal is diabetes management or weight loss.

Patients choose compounded semaglutide for three reasons:

1. Lower cost (typically $200 to $400/month vs $900 to $1,400 for brand-name)
2. Shortage of brand-name product
3. Insurance denial of brand-name product for off-label use

The clinical effects are the same. The mechanism is the same. The side-effect profile is the same. The difference is regulatory status and cost.

FormBlends connects patients with licensed providers who can prescribe compounded semaglutide when clinically appropriate. All prescribing decisions are made by independent licensed providers, and all compounding is performed by U.S.-based 503A pharmacies.

When to choose Ozempic vs other GLP-1 medications

The GLP-1 agonist class includes:

• Semaglutide (Ozempic, Wegovy, Rybelsus)
• Liraglutide (Victoza, Saxenda)
• Dulaglutide (Trulicity)
• Tirzepatide (Mounjaro, Zepbound) - technically a dual GLP-1/GIP agonist
• Exenatide (Byetta, Bydureon)

Choose Ozempic (or compounded semaglutide at Ozempic doses) when:

• The primary goal is type 2 diabetes management
• The patient has cardiovascular disease and needs proven MACE reduction
• Once-weekly injection is preferred over daily (liraglutide requires daily injection)
• The patient has tried metformin or sulfonylureas and needs additional A1C reduction

Choose Wegovy (or compounded semaglutide at Wegovy doses) when:

• The primary goal is weight loss and the patient does not have diabetes
• The patient has obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidity
• Maximum weight-loss efficacy is the priority

Choose tirzepatide (Mounjaro or Zepbound) when:

• Greater A1C reduction is needed (tirzepatide produces 2.0 to 2.5% A1C reduction vs 1.5 to 2.0% for semaglutide)
• Greater weight loss is needed (tirzepatide produces 15 to 22% weight loss vs 10 to 15% for semaglutide)
• The patient has tried semaglutide and had inadequate response

Choose liraglutide when:

• The patient cannot tolerate once-weekly injections (some patients prefer daily dosing for perceived control)
• The patient has a history of pancreatitis and needs the GLP-1 with the longest safety record (liraglutide was approved in 2010, earlier than others)

Choose dulaglutide when:

• The patient wants once-weekly dosing but has had GI side effects on semaglutide (dulaglutide has a slightly different side-effect profile)

The choice is individualized. No GLP-1 agonist is universally superior. Semaglutide (Ozempic/Wegovy) has the best combination of efficacy, dosing convenience, and clinical trial data, which is why it's the most commonly prescribed. Tirzepatide is emerging as the most effective option for both diabetes and weight loss but is newer and has less long-term safety data.

FAQ

What is Ozempic FDA-approved for? Ozempic is FDA-approved for two indications: improving blood sugar control in adults with type 2 diabetes, and reducing the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established heart disease. It is not FDA-approved for weight loss.

Can Ozempic be prescribed for weight loss? Yes, prescribing Ozempic for weight loss is legal and common, but it is off-label. Insurance typically does not cover off-label use, so patients usually pay cash. Wegovy (same ingredient, higher dose) is the FDA-approved option for weight loss and may be covered by insurance if the patient meets criteria.

What does Ozempic do to your body? Ozempic activates GLP-1 receptors, which increases insulin secretion when blood sugar is high, decreases glucagon (a hormone that raises blood sugar), slows stomach emptying, and reduces appetite. The result is lower blood sugar, reduced hunger, and weight loss.

How much weight do people lose on Ozempic? At the 1 mg weekly dose, average weight loss is 10 to 15 pounds over 6 to 12 months. At the 2 mg dose, average loss is 12 to 18 pounds. Individual results vary widely. About 10% of patients lose more than 10% of body weight; about 20% lose less than 5%.

Is Ozempic the same as Wegovy? Yes and no. Both contain semaglutide. Ozempic is approved for diabetes and dosed up to 2 mg weekly. Wegovy is approved for weight loss and dosed at 2.4 mg weekly. The higher Wegovy dose produces about 5 to 10 pounds more weight loss on average.

What is the difference between Ozempic and Mounjaro? Ozempic contains semaglutide (a GLP-1 agonist). Mounjaro contains tirzepatide (a dual GLP-1 and GIP agonist). Mounjaro produces greater A1C reduction (2.0 to 2.5% vs 1.5 to 2.0%) and greater weight loss (15 to 22% vs 10 to 15%) but costs more and has a shorter track record.

Does Ozempic work if you don't have diabetes? Yes. The appetite suppression and delayed gastric emptying effects work regardless of baseline glucose levels. The STEP trials tested semaglutide in patients without diabetes and showed 15% average weight loss at the 2.4 mg dose (Wegovy dose). Ozempic doses produce less weight loss but still work.

How long does it take for Ozempic to work? For blood sugar control, most patients see A1C reduction within 4 to 8 weeks. For weight loss, most patients notice reduced appetite within 1 to 2 weeks and see measurable weight loss (5+ pounds) within 8 to 12 weeks. Maximum effect occurs at 20 to 30 weeks.

What happens when you stop taking Ozempic? Blood sugar control deteriorates within 4 to 8 weeks. Weight regain begins within 8 to 12 weeks. In the STEP-1 withdrawal study, patients regained two-thirds of lost weight within 12 months of stopping semaglutide (Wilding et al., Diabetes Obesity and Metabolism, 2022). Ozempic is a chronic medication, not a short-term fix.

Can you take Ozempic if you're not overweight? If you have type 2 diabetes, yes. Ozempic is indicated for diabetes regardless of weight. If you don't have diabetes and are not overweight, prescribing Ozempic would be off-label and not supported by clinical evidence. GLP-1 agonists are not appropriate for cosmetic weight loss in normal-weight individuals.

Does insurance cover Ozempic for weight loss? Rarely. Most commercial insurance and Medicare Part D cover Ozempic only for type 2 diabetes. For weight loss without diabetes, Wegovy is the labeled option, but coverage varies by plan. Many plans exclude weight-loss medications entirely. Patients often pay cash or use compounded semaglutide as a lower-cost alternative.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient (semaglutide) and works through the same mechanism. The difference is regulatory status: Ozempic is FDA-approved and manufactured under GMP standards; compounded semaglutide is prepared by state-licensed pharmacies and not FDA-approved. Clinical effects are equivalent when dosed identically.

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinology. 2017.
5. Ahmann AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3). Diabetes Care. 2018.
6. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinology. 2018.
7. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022.
8. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
9. Radley DC et al. Off-label prescribing among office-based physicians. Archives of Internal Medicine. 2006.
10. FDA. Ozempic (semaglutide) injection prescribing information. 2017, revised 2022.
11. FDA. Wegovy (semaglutide) injection prescribing information. 2021.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
13. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Victoza, Saxenda, Trulicity, Mounjaro, Zepbound, Byetta, and Bydureon are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.